Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II Trial  by Flores, Raja M. et al.
ORIGINAL ARTICLE
Induction Chemotherapy, Extrapleural Pneumonectomy,
and Postoperative High-Dose Radiotherapy for Locally
Advanced Malignant Pleural Mesothelioma: A Phase II Trial
Raja M. Flores, MD,* Lee M. Krug, MD,† Kenneth E. Rosenzweig, MD,‡
Ennapadam Venkatraman, PhD,§ Alain Vincent, BS,* Robert Heelan, MD,¶ Tim Akhurst, MD,¶
and Valerie W. Rusch, MD*
Introduction: Extrapleural pneumonectomy (EPP) and adjuvant
high-dose radiation therapy (RT) are associated with a median
survival of 3 years in early-stage malignant pleural mesothelioma
(MPM) but of less than 1 year in locally advanced disease. Although
local control after EPP and RT is excellent, most patients die of
distant metastases. We designed this clinical trial to test the feasi-
bility of induction chemotherapy followed by EPP and RT in locally
advanced MPM with the ultimate aim of improving survival.
Methods: Patients with MPM and stage III or IV disease were
eligible. Induction therapy was four cycles of gemcitabine and
cisplatin. Patients without disease progression by computed tomog-
raphy underwent EPP followed by adjuvant hemithoracic RT (54
cGy).
Results: From January 2002 to January 2004, 21 patients (17 men,
four women; median age 60 years) were entered into the study.
Histology was epithelioid in 14 patients and mixed or sarcomatoid
five patients. Pretreatment disease stage was III in 13 patients and IV
in six patients. Nineteen patients received induction chemotherapy.
Response to induction therapy was complete in zero patients, partial
in five patients, stable disease in six patients, and progression of
disease in eight patients. Eight of nine patients undergoing surgical
exploration had EPP. The median survival of all patients was 19
months. Patients who had an EPP had a median survival of 33.5
months. Patients with unresectable tumors had a median survival of
9 months (p  0.01).
Conclusion: Induction chemotherapy with gemcitabine and cispla-
tin followed by EPP and adjuvant RT for locally advanced MPM is
feasible and leads to a better median overall survival than that
previously reported with EPP and RT alone.
Key Words: Extrapleural pneumonectomy, Induction chemother-
apy, Mesothelioma.
(J Thorac Oncol. 2006;1: 289–295)
Therapy for malignant pleural mesothelioma (MPM) re-mains controversial, with little agreement regarding stan-
dards of care. The role of surgery in MPM, especially EPP,
has been especially controversial because of high operative
mortality reported in early series and uncertainty about sur-
vival benefit.1,2 However, recent studies incorporating EPP
report a surgical mortality of 6% or less, comparable to that
of standard pneumonectomy.3,4 This finding has led to a more
widespread use of EPP for carefully selected patients and the
development of multimodality therapy for MPM. A phase II
trial conducted at Memorial Sloan-Kettering showed that a
combination of resection by EPP followed by adjuvant high-
dose external beam hemithoracic radiotherapy (EBRT) is
tolerable and associated with excellent local control.5 With
this approach, patients with stage I or II disease had a 3-year
median survival, but those with stage III or IV disease had a
median survival of less than 1 year. Local control was
achieved in 90% of cases, and the most common sites of
relapse were distant metastases. Based on this experience, we
considered that there may be a rationale for adding chemo-
therapy to EPP and EBRT to reduce the risk of systemic
relapse and potentially improve survival.
Until recently, chemotherapy has not been effective in
MPM. However, newer drugs are well tolerated and have
yielded encouraging response rates. In a single-institution
study, the combination of gemcitabine and cisplatin yielded a
response rate of 48% in previously untreated patients with
MPM.6 Although the response rates to this regimen proved to
be lower (26% to 33%) in subsequent multicenter trials, the
combination of cisplatin and gemcitabine was widely consid-
ered the best tolerated, most effective chemotherapy regimen
at the time we designed this trial.7,8 Therefore, we designed
this trial to evaluate the feasibility of adding induction gem-
citabine and cisplatin to our established approach of EPP and
EBRT, focusing on patients known to have the poorest
survival and the highest risk of metastatic disease.
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PATIENTS AND METHODS
Design
This was a single-institution, prospective, single-arm
trial conducted to determine the feasibility and potential
efficacy of preoperative chemotherapy with gemcitabine and
cisplatin, followed by EPP and adjuvant high-dose hemitho-
racic EBRT in patients with locally advanced malignant
pleural mesothelioma (stage III or IV). The schema for this
study is shown in Figure 1.
Pretreatment Evaluation
This trial was approved by our institutional review
board, and all patients were required to sign written informed
consent within 30 days before therapy. Baseline evaluations
included a complete history and physical examination, record
of performance status, and blood tests including complete
blood count and chemistry panel. Imaging studies included
computed tomography (CT) of the chest and upper abdomen
(with intravenous contrast) to the level of the adrenals.
Positron emission tomography (PET) was recommended but
not required. Complete pulmonary function testing (including
diffusion capacity, rest and exercise arterial blood gases),
quantitative ventilation perfusion scan, and radionuclide
stress tests were obtained for all patients.
Inclusion Criteria
All patients were required to have a pathologic diag-
nosis of MPM confirmed at Memorial Sloan-Kettering Can-
cer Center and to be clinically staged as T3-4, N0-2, M0
based on CT scan findings.9 Patients were evaluated by a
medical oncologist, thoracic surgeon, and radiation oncolo-
gist before enrollment into the study. Patients were required
to have a Karnofsky performance status 70% and initial
laboratory values including white blood cell 3000/mm3,
platelet count 100,000/mm3, hemoglobin 8 mg/dl, serum
creatinine 1.5, and bilirubin  1.9. Pulmonary function
evaluation required the postoperative predicted forced expi-
ratory volume in 1 second and single breath diffusing capac-
ity to be at least 35%. Patients not eligible for this protocol
included those with previous surgical resection, chemother-
apy, or radiation therapy for MPM; clinically apparent hear-
ing loss; or medical illness not controlled by appropriate
medical therapy. Any other prior malignancy except me-
sothelioma was allowed if a 5-year disease-free interval had
elapsed since last treatment.
Chemotherapy
Induction chemotherapy included gemcitabine admin-
istered at a dose of 1250 mg/m2 on days 1 and 8 and cisplatin
75 mg/m2 on day 8 repeated every 21 days for two cycles.
The patient then underwent reevaluation by CT scan of the
chest and upper abdomen. If the tumor was stable or respond-
ing to therapy, the patient received two more cycles of
chemotherapy for a total of four cycles. Routine guidelines
for hydration and antiemetic therapy were followed, and
standard dose adjustments were required for hematologic,
renal, and neural toxicity.
Surgery
All patients underwent exploratory thoracotomy unless
there was progression of disease or deterioration of pulmo-
nary function such that pneumonectomy would be intolera-
ble. EPP was performed as previously described and included
en bloc resection of the pleura, lung, diaphragm, and, if
indicated, pericardium.10 The diaphragm was reconstructed
with either Dexon mesh (U.S. Surgical, Norwalk, CT) or
Gore-Tex prosthetic material (W.L. Gore & Associates, Inc.,
Flagstaff, AZ), and the pericardium was reconstructed with
Dexon mesh. At thoracotomy, patients had a complete me-
diastinal lymph node dissection, including the subcarinal
nodes (level 7), azygous and paratracheal nodes (levels 10
and 4) on the right, and the subcarinal nodes (level 7) and
aorticopulmonary nodes (levels 5 and 6) on the left. Patients
found to have incompletely resectable or unresectable tumors
at thoracotomy were removed from the study.
Hemithoracic Radiation
All patients who underwent EPP received adjuvant
hemithoracic EBRT starting 3 to 6 weeks postoperatively. All
patients had treatment planning CT scans. A total of 5400FIGURE 1. Protocol schema
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cGy in 30 fractions of 1.80 cGy per day was administered per
our previously described protocol. The target volume in-
cluded the hemithorax and chest wall incisions. The spinal
cord was protected after 4140 cGy. Cerrobend blocks limited
the dose to the liver, heart, and stomach. Electrons were used
in blocked regions to dose the diaphragm and chest wall
adequately.5,11
Response Evaluation
CT assessment of MPM lesions followed the guidelines
of the Response Evaluation Criteria in Solid Tumors Group.12
Each patient had a baseline pretreatment CT scan. All tumor
lesions were classified as measurable or non-measurable by a
single radiologist, and measurable disease was, on average,
1 cm in maximal diameter. If the patient had a measurable
lesion (as defined above), a series of three to five reproducible
representative sections of tumor thickness (target lesions)
were measured. To assure accuracy and consistency when
subsequent scans were compared, the image number, image
window, and tumor thickness were recorded for each mea-
sured section. The thickness measurements were added to
obtain the baseline sum longest diameter. This measurement
was used to compare subsequent scans after induction che-
motherapy to determine whether there was a response.
Complete response was defined as the disappearance of
all target lesions. A partial response was defined as a 30%
decrease in the sum of the longest diameter of target lesions,
taking as a reference the baseline sum longest diameter.
Progressive disease was defined as at least a 20% increase in
the sum of the longest diameter of target lesions, taking as a
reference the smallest sum longest diameter recorded since
treatment started or the appearance of one or more new
lesions. Stable disease was defined as neither sufficient
shrinkage to qualify for partial response nor sufficient in-
crease to qualify for progressive disease, taking as a reference
the smallest sum longest diameter since treatment started.
Adverse Events
All adverse events were graded according to the Na-
tional Cancer Institute Common Terminology Criteria for
Adverse Events version 3.0.
Removal of Patients from Protocol Therapy
Any patient with disease progression was removed
from study. The development of unacceptable toxicity, de-
fined as unpredictable, irreversible, or grade 4 toxicity (ex-
cluding myelosuppression and mucositis) required patient
removal from the study. If the thoracic surgeon deemed the
patient an unsuitable surgical candidate after induction ther-
apy, the patient was removed from the study. If a patient
experienced a decline in performance status while receiving
therapy, the principal investigator determined whether study
removal was appropriate.
Statistics
This treatment regimen would be considered feasible if
it could be administered without serious adverse events. The
primary objective was the assessment of response, defined as
complete response plus partial response to induction chemo-
therapy. A background rate of 5% was considered unaccept-
able. Because earlier studies of gemcitabine and cisplatin
have reported response rates ranging from 18% to 48%, a
20% response rate would be considered promising. A Simon
two-stage phase II design was used, and the error rates for
accepting an uninteresting drug and rejecting a promising one
were set at 10% each.13 In the first stage, we would treat 12
patients. If none showed a response, the study would be
stopped. If one or more responses were seen, an additional 25
patients (for a total of 37) would be added. If four or more
responses were seen, then the drug would be considered
promising. The response rate would be estimated at the end of
the trial. The anticipated accrual rate was approximately one
patient per month with total trial duration of 3 years. Overall
survival was estimated using the method of Kaplan-Meier.
RESULTS
Demographics
From January 2002 to January 2004, 21 patients were
entered into the study, and 19 underwent chemotherapy. One
patient who initially consented to induction chemotherapy
subsequently decided to go directly to surgery. One patient
initially thought to have MPM was subsequently found to
have thymic carcinoma and was deemed ineligible for the
study. The median age of all patients was 60 years (range,
37-71 years). The racial and gender distribution included 18
white (95%) and 1 Hispanic (5%) patients, and 15 men (79%)
and four women (21%), respectively. There were nine right-
sided (47%) and 10 left-sided (53%) cases. Tumor histology
included 14 epithelioid, four mixed, and one sarcomatoid
tumor. Based on CT imaging, pretreatment clinical stage was
III for 13 and IV for six patients (T3N0 for nine, T3N2 for
four, T4N0 for three, and T4N2 for three patients) (Table 1).
TABLE 1. Patient characteristics
Age (yr) 61 (37–72)
Sex
Male 15 (79)
Female 4 (21)
Race
White 18 (95)
Hispanic 1 (5)
Laterality
Right 9 (47)
Left 10 (53)
Performance status at entry on study
KPS 90/100 14 (74)
KPS 80 5 (26)
Histology
Epithelioid 14 (74)
Mixed 4 (21)
Sarcomatoid 1 (5)
Clinical stage I/II Pathological stage II 0/2
Clinical stage III/Pathological stage III 13/3
Clinical stage IV/Pathological stage IV 6/4
Values are median (age) or n (%). KPS, Karnofsky Performance Status.
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Chemotherapy
Ten patients completed four cycles of chemotherapy.
Four patients completed two cycles of chemotherapy but
showed progression of disease on repeat imaging. Five pa-
tients underwent only one cycle of chemotherapy because of
progression of disease in four cases and deteriorating perfor-
mance status in one patient. Chemotherapeutic responses
were: complete response in no patients, partial response in
five (26%; 95% confidence interval 9% to 51%), stable
disease in six (32%), and progression of disease in eight
patients (42%).
Surgery
Nine patients were eligible for surgical exploration, and
eight were found to have resectable tumors by EPP. The
patient found to have unresectable disease had undergone a
previous thoracotomy, reportedly for biopsy alone, but at
exploration had clearly undergone an extensive pleurectomy
and consequently had a tumor diffusely invading the chest
wall. Three patients with clinical stage IV disease had resect-
able tumors but remained stage IV by surgical-pathological
staging. Of the five patients with clinical stage III disease,
two were down-staged to stage II and three remained stage III
at surgical-pathological evaluation.
Radiotherapy
All patients completing EPP began EBRT within 6
weeks postoperatively. All patients received the predeter-
mined dose of 54 cGy except one patient who refused
treatment after receiving 5040 Gy. One patient developed a
bronchial stump leak after radiotherapy, which was managed
with an Eloesser flap.
Adverse Events
Chemotherapeutic toxicity is summarized in Table 2a.
Grade 3 and 4 hematologic toxicity included anemia, leuko-
penia, neutropenia, and thrombocytopenia. A saddle pulmo-
nary embolus occurred in one patient who subsequently
underwent EPP after IVC (inferior vena cava) filter place-
ment and anticoagulation. Most patients experienced minor
fatigue and gastrointestinal symptoms.
There were no grade 4 surgical complications. An
empyema occurred in one patient who required an Eloesser
flap, and hemorrhage occurred in another and required sur-
TABLE 2A. Chemotherapy toxicity and grade
Complication
Grade 1
Mild
Grade 2
Moderate
Grade 3
Severe
Grade 4
Life-threatening
or disabling
Grade 5
Death
Anemia – – 1 – –
DVT – – 1 – –
Dyspnea – – 1 – –
Fatigue 5 2 1 – –
Fever 2 – – – –
Leukopenia – – 1 – –
LUE swelling 1 – – – –
Nausea 5 3 – – –
Neutropenia – 2 1 1 –
Pulmonary embolus – 1 – – –
Rash – 2 – – –
Renal insufficiency – 1 – – –
Stomatitis – 2 – – –
Thrombocytopenia – – 1 – –
Vomiting 2 2 – – –
TABLE 2B. Surgical toxicity and grade
Complication
Grade 1
Mild
Grade 2
Moderate
Grade 3
Severe
Grade 4
Life-threatening
or disabling
Grade 5
Death
Atrial fibrillation – 1 – – –
Line infection – 2 – – –
Dehydration – 1 – – –
Empyema – – 1 – –
Hemorrhage – – 1 – –
Hypotension – 1 – – –
Wound infection 1 – – – –
Values are median (age) or n (%). KPS, Karnofsky Performance Status.
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gical re-exploration. Surgical complications are summarized
in Table 2b.
Radiation toxicity is summarized in Table 2c. Hemato-
logic toxicity occurred in one patient with anemia. Low-grade
complications included esophagitis and weight loss. Two
patients developed upper-extremity deep venous thromboses
requiring anticoagulation.
There were no adverse events that precluded the con-
tinuation of the study. However, the study was closed pre-
maturely because of the initiation of a study using pem-
etrexed and cisplatin in the neoadjuvant setting.
Survival
The median follow-up of all surviving patients was 9
months. The median survival of all patients with advanced
stage MPM included in the study was 19 months (Fig. 2). The
patients who underwent EPP had a median survival of 33.5
months, whereas patients who were unable to undergo resec-
tion had a median survival of 9.7 months (log rank p  0.01)
(Fig. 3). Of the eight patients who underwent EPP, three are
alive without disease, four experienced recurred tumor at
distant sites, none recurred locally, and one died a year
postoperatively from pneumonia but had no evidence of
recurrent disease. The trial was stopped prematurely because
of a new competing protocol.
DISCUSSION
The treatment of MPM remains controversial but has
evolved considerably during the past 20 years. Advances in
the management of MPM include easier and more accurate
methods of pathological diagnosis, a better understanding of
the natural history of the disease, improved methods of
staging and of selecting patients for surgery, a significant
decrease in operative mortality (especially for EPP), marked
improvements in local control with combined resection and
high-dose adjuvant radiation, better systemic therapies, and
emerging insights into tumor biology3–8,10,11,14–18. The
present study is one of a very small number of prospective
clinical trials designed to test novel multimodality therapy for
MPM. It builds logically on both our previous retrospective
studies and prospective clinical trials that showed an opera-
tive mortality of 6% or less for EPP in carefully selected
patients, and excellent local control (risk of local recurrence
of less than 10%) in patients who receive high-dose (54Gy)
hemithoracic radiation after EPP.3–5 In the latter trial,5 we
found that the median survival of patients who had stage I or
II tumors was almost 3 years, whereas the patients who had
stage III or IV disease had a median survival of less than 1
year because of the development of distant metastases. Our
rationale in developing this most recent trial was that the
TABLE 2C. Radiotherapy toxicity and grade
Complication
Grade 1
Mild
Grade 2
Moderate
Grade 3
Severe
Grade 4
Life-threatening
or disabling
Grade 5
Death
Anemia – – 1 – –
Deep venous thrombosis – 2 – – –
Esophagitis – 3 – – –
Fatigue 2 – – – –
Nausea 1 2 – – –
Odynophagia 1 – – – –
Pain 2 – – – –
Shingles 2 – – – –
FIGURE 2. Kaplan Meier survival curve and confidence in-
tervals of all patients.
FIGURE 3. Kaplan Meier survival curves of EPP patients and
those without surgical resection.
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addition of induction chemotherapy to EPP and hemithoracic
radiation would be feasible and might decrease the risk of
systemic relapse, thereby improving survival. We thought
that the most appropriate patient population in which to test
this potentially more toxic multimodality approach would be
the patients at highest risk of disease progression, namely
those with stage III or IV tumors.
The eligibility criteria for this trial were identical to
those used in our previous trial of EPP and hemithoracic
radiation,5 except that we confined study entry to patients
with locally advanced disease. Since the design of this trial,
we have shown that fludeoxyglucose-PET is a useful tool in
the initial staging of MPM because it detects metastatic
disease in approximately 10% more cases than CT, and
because the standardized uptake value on PET is an indepen-
dent predictor of overall survival.16,19,20 However, because
these data did not exist at the time this trial was designed,
PET could not be included as a required pretreatment imaging
study. Likewise, mediastinoscopy can be used to identify
patients who have a poorer prognosis because of mediastinal
nodal metastases. This was allowed but not required as an
initial staging study in this trial because mediastinoscopy fails
to identify the presence of mediastinal nodal metastases in at
least 25% of patients3 and because our experience is that
patients with locally advanced disease (T3 or T4) can usually
be identified by CT scan. Magnetic resonance imaging, which
is sometimes used as a staging tool for MPM, was also not
required because we previously found that it did not add
information to CT imaging often enough to warrant its
routine use.21 Certainly, future trials aiming to enroll highly
selected groups of patients might use some or all of these
staging modalities in addition to CT. Indeed, based on the
recent experience with PET, a current ongoing multicenter
trial testing the use of multimodality therapy in MPM in-
cludes PET as a pretreatment study.
Likewise, we chose to enroll patients in this trial
irrespective of tumor histology. Although mixed and sarco-
matoid tumor histologies are known to be associated with a
worse prognosis than epithelioid tumors,3,4 we believe that it
is useful in this study and in future trials to gain an estimate
of the feasibility and potential efficacy of multimodality
therapy across all histologies. At some future time, it may
become appropriate to restrict study entry or to stratify
patients according to tumor histology, especially if certain
chemotherapeutic agents prove to be more efficacious in
individual tumor subtypes.
A nearly contemporaneous trial of similar design and
size recently reported by Weder et al.17 corroborates our
experience regarding the feasibility of induction chemother-
apy (also cisplatin and gemcitabine), EPP, and adjuvant
radiation. Additional multicenter experience with this same
multimodality approach in approximately 60 patients was
recently presented by the Swiss cooperative group.22 In the
Swiss experience, the addition of chemotherapy also seemed
to influence median and overall survival favorably.17,20 The
cumulative experiences from our institution and from the
Swiss group provide a solid rationale for further testing of
this multimodality approach in MPM. However, there are
important differences between our trial and the Swiss expe-
rience. The Swiss trials enrolled patients who had early-stage
disease. They also did not use postoperative high-dose
hemithoracic radiation, a treatment component that is poten-
tially toxic but also more likely to achieve local control. Our
experience has led the Swiss group to undertake a random-
ized multimodality trial aimed at confirming the benefit of
adjuvant high-dose hemithoracic radiation. Conversely, the
Swiss experience has provided the rationale for offering
induction chemotherapy to patients who have stage I and II
disease rather than just those with more locally advanced
disease.
While both this trial and the Swiss trials were nearing
their accrual goals, a prospective randomized international
trial showed that the combination of cisplatin and pemetrexed
was superior to cisplatin alone (as measured by response and
overall survival) in patients with MPM who were not candi-
dates for resection.14 Although no direct comparison exists
between cisplatin and pemetrexed and cisplatin and gemcit-
abine, the excellent trial results and the patient tolerance of
cisplatin and pemetrexed quickly led to this becoming the
most widely used initial chemotherapy regimen in MPM, and
led us to close our trial. These results also led to the devel-
opment of a multicenter trial testing cisplatin and pemetrexed
as induction therapy in patients with earlier stage disease who
are considered potential candidates for resection via EPP. The
design of that multicenter trial was directly based on our
study and includes four cycles of preoperative chemotherapy
as well as adjuvant high-dose hemithoracic radiation after
EPP. Modifications in trial design included the addition of
PET for pretreatment staging and the inclusion of patients
who have stage I and II disease as well as stage III disease. To
date, more than 70 patients have been enrolled into the study,
and it is expected that the trial will complete accrual in the
coming year. Unquestionably, our trial and those of similar
design address a carefully selected patient cohort but show
the feasibility of this multimodality treatment and suggest the
potential of improved outcome for some patients with MPM.
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